At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 190 enrolled

Drug / intervention

Nivolumab +4 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02935634

NCT02935634Phase 2Completed

Compare CT.gov

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)

Bristol-Myers Squibb·interventional·Posted Oct 17, 2016·Updated Jun 9, 2023

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 3 other interventions for Advanced Gastric Cancer. Completed, enrolled 190 participants across 35 sites in 9 countries.

Detailed Summary

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAdvanced Gastric Cancer

CountriesAustralia, Canada, Germany, Israel, Italy, Netherlands, Singapore, Switzerland, United States

CollaboratorsClovis Oncology, Inc.

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedOct 2016

Enrollment StartNov 2016

Primary CompletionMay 2022

TodayJul 2026

First PostedOct 17, 2016

Enrollment StartNov 29, 2016

Primary CompletionMay 11, 2022

TodayJul 2, 2026

Enrollment to primary: 5.5 yearsPosted 9.7 years ago